← Browse by Condition
Medical Condition

cyp2c19 polymorphism

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 4

ClinicalMetric tracks all active clinical trials for cyp2c19 polymorphism sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — cyp2c19 polymorphism Clinical Trials

How many clinical trials are currently recruiting for cyp2c19 polymorphism?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for cyp2c19 polymorphism, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for cyp2c19 polymorphism?
cyp2c19 polymorphism research spans Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a cyp2c19 polymorphism clinical trial?
Eligibility criteria for cyp2c19 polymorphism trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 4
1
Top Sponsors
University of Virginia 1 trial
Zunyi Medical College 1 trial

Recruiting Clinical Trials

NCT06292117
Recruiting
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
Enrollment
350 pts
Location
United States
Sponsor
University of Virginia
View Trial →
NCT06283888 Phase 4
Recruiting
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
Enrollment
1,200 pts
Location
China
Sponsor
Zunyi Medical College
View Trial →

Related Conditions

ischemic stroke (1) acs acute coronary syndrome (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology